DB
ALXN

Dmitry Balyasny’s Alexion Pharmaceuticals ALXN Stock Holding History

Dmitry Balyasny’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-80,000
Closed -$9.15M – 1849
2020
Q3 		$9.15M Buy
+80,000
New +$8.63M 0.07% 409

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Dmitry Balyasny's ALXN Position: Q3 2021 in Review

Dmitry Balyasny sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 771,620 shares — an estimated $142M sold.

Dmitry Balyasny first reported a position in ALXN in Q2 2014 and held it in 26 quarters. The position peaked at $147M in Q4 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Dmitry Balyasny reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Dmitry Balyasny sold 771,620 Alexion Pharmaceuticals shares in Q3 2021, an estimated $142M.
  • Dmitry Balyasny first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 26 quarters.
  • Dmitry Balyasny's Alexion Pharmaceuticals position peaked at $147M in Q4 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.